BioPharm International-05-01-2019

BioPharm International

Getting a Handle on Biopharma’s Most Critical Quality Attributes and Quality Control

May 01, 2019

Features

32

5

While the multiple attributes method gains ground and traditional lab methods improve, broad efforts are underway to determine biopharmaceuticals’ most significant critical quality attributes and enable real-time release.

FDA Faces Challenges After Gottlieb

May 01, 2019

Regulatory Beat

32

5

New agency leadership is pressed to promote innovation while addressing safety and quality issues.

Bioprocessing Facilities and FDA Inspection Problems

May 01, 2019

Perspectives on Outsourcing

32

5

FDA inspections can create uncertainty. Supervision of the contract manufacturer is crucial in ensuring compliance.

The Auditor Vs. Inspector Issue

May 01, 2019

Ask the Expert

32

5

We need to understand both sides when it comes to audits, says Siegfried Schmitt, PhD, vice-president, technical, PAREXEL Consulting.

Challenges with Successful Commercialization of Biosimilars

May 01, 2019

Features

32

5

This article presents some key differences between the US and European regulation of biosimilars, including naming conventions and pharmacovigilance of biosimilars, and the impact of biosimilars on commercialization and affordability of biotherapeutics.

Working for the Greater Good

May 01, 2019

From the Editor

32

5

Pharma delivers a positive message with renewed efforts to eradicate malaria.

BioPharm International, May 2019 Issue (PDF)

May 01, 2019

Issue PDF

32

5

Click the title above to open the BioPharm International May 2019 issue in an interactive PDF format.